HomeNewsIndiaSEBI feels mutual funds have full flexibility on PTCs, no further relaxations needed

SEBI feels mutual funds have full flexibility on PTCs, no further relaxations needed

PTCs are certificates given to the investors including banks and mutual funds, where repayment comes from a basket or pool of underlying loans, usually loans taken by individuals.

April 12, 2020 / 15:02 IST
Story continues below Advertisement

In the wake of the COVID-19 crisis, mutual funds have been given a number of relaxations by regulator Sebi and they have got full flexibility regarding the valuation of Pass-Through Certificates including in case of the moratorium on underlying loans, officials said on Sunday. PTCs are certificates given to the investors including banks and mutual funds, where repayment comes from a basket or pool of underlying loans, usually loans taken by individuals. PTCs are usually issued by NBFCs, through a trust structure.

Officials said the fund houses already have sufficient flexibility under various Sebi regulations on valuation of PTCs and therefore no further relaxations are required to deal with the moratorium situation arising out of the COVID-19 crisis.

Story continues below Advertisement

Recently, the industry body of mutual funds, the Association of Mutual Funds in India (AMFI), had written to Sebi regarding relaxation relating to valuation of PTCs if underlying loans are given a moratorium.

"On account of COVID related disruption, there is apprehension that there could be defaults in payment of interest or principal to the investors who have bought PTCs since interest and principal payments on PTCs is dependent on cash flows from the underlying loan pools," a senior official of an Asset Management Company (AMC) said.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show